Diabetes Mellitus, Hypercholesterolemia, and Hypertension but Not Vascular Disease Per Se Are Associated With Persistent Platelet Activation In Vivo
- 1 July 1997
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 96 (1) , 69-75
- https://doi.org/10.1161/01.cir.96.1.69
Abstract
Background Previous studies relating increased thromboxane (TX) biosynthesis to cardiovascular risk factors do not answer the question whether platelet activation is merely a consequence of more prevalent atherosclerotic lesions or reflects the influence of metabolic and hemodynamic disturbances on platelet biochemistry and function. Methods and Results We examined 64 patients with large-vessel peripheral arterial disease and 64 age- and sex-matched control subjects. TXA 2 biosynthesis was investigated in relation to cardiovascular risk factors by repeated measurements of the urinary excretion of its major enzymatic metabolite, 11-dehydro-TXB 2 , by radioimmunoassay. Urinary 11-dehydro-TXB 2 was significantly ( P =.0001) higher in patients with peripheral arterial disease (57±26 ng/h) than in control subjects (26±7 ng/h). Seventy percent of patients had metabolite excretion >2 SD above the normal mean. However, 11-dehydro-TXB 2 excretion was enhanced only in association with cardiovascular risk factors. Multivariate analysis showed that diabetes, hypercholesterolemia, and hypertension were independently related to 11-dehydro-TXB 2 excretion. During a median follow-up of 48 months, 8 patients experienced major vascular events. These patients had significantly ( P =.001) higher 11-dehydro-TXB 2 excretion at baseline than patients who remained event free. Conclusions The occurrence of large-vessel peripheral arterial disease per se is not a trigger of platelet activation in vivo. Rather, the rate of TXA 2 biosynthesis appears to reflect the influence of coexisting disorders such as diabetes mellitus, hypercholesterolemia, and hypertension on platelet biochemistry and function. Enhanced TXA 2 biosynthesis may represent a common link between such diverse risk factors and the thrombotic complications of peripheral arterial disease.Keywords
This publication has 39 references indexed in Scilit:
- Inhibition of Thromboxane Biosynthesis and Platelet Function by Simvastatin in Type IIa HypercholesterolemiaArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Thromboxane biosynthesis and metabolism in relation to cardiovascular risk factorsTrends in Cardiovascular Medicine, 1992
- Overview of patency as an end point of thrombolytic therapyThe American Journal of Cardiology, 1991
- Mechanisms of platelet activation: Thromboxane A2 as an amplifying signal for other agonistsThe American Journal of Cardiology, 1991
- Thromboxane Biosynthesis and Platelet Function in Type II Diabetes MellitusNew England Journal of Medicine, 1990
- Prostacyclin and thromboxane biosynthesis in mild essential hypertension.Hypertension, 1990
- Platelet Activation in Unstable Coronary DiseaseNew England Journal of Medicine, 1986
- Increased Prostacyclin Biosynthesis in Patients with Severe Atherosclerosis and Platelet ActivationNew England Journal of Medicine, 1984
- Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease.Circulation, 1983
- β-Thromboglobulin, Platelet Production Time and Platelet Function in Vascular DiseaseBritish Journal of Haematology, 1979